John L. Wagner MD

Oncology•Charlottesville, VA

Hematologic Oncology

Hematopoietic Stem Cell Transplantation/ Univ of Virginia Healthcare

Join to View Full Profile

1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-9333
Fax+1 434-244-7526

Summary

Dr. John Wagner is an oncologist in Charlottesville VA and is affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Temple University School of Medicine and has been in practice 28 years. He specializes in cellular therapy and hematopoietic stem cell transplantation and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and CAR-T therapy.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1989 - 1992
Lewis Katz School of Medicine at Temple UniversityClass of 1989

Certifications & Licensure

OH State Medical License 2025 - 2027
WV State Medical License 2023 - 2027
PA State Medical License 1999 - 2026
VA State Medical License 2022 - 2026
DE State Medical License 2017 - 2023
NJ State Medical License 2017 - 2023
MD State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2020-2022
Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013

Clinical Trials

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
COMPLETED
PHASE2
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
COMPLETED
PHASE1, PHASE2
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05
COMPLETED
PHASE2
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies Start of enrollment: 2008 Apr 10
COMPLETED
PHASE2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
COMPLETED
PHASE2
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors Start of enrollment: 2011 Feb 10
Completed
Phase 2
Treatment of Sickle Cell Anemia With Stem Cell Transplant
TERMINATED
NA
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Start of enrollment: 2011 May 25
TERMINATED
PHASE1
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Start of enrollment: 2011 Aug 04
Completed
Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
COMPLETED
PHASE1, PHASE2
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
WITHDRAWN
NA
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Start of enrollment: 2012 Dec 24
COMPLETED
PHASE2
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Mar 15
COMPLETED
EARLY_PHASE1
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
ACTIVE_NOT_RECRUITING
PHASE2
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 May 17
TERMINATED
PHASE2
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Start of enrollment: 2013 Nov 04
COMPLETED
PHASE2
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
A Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant,...
Xia Bi, Dolores Grosso, Allison Gradone, Joanne Filicko-O'Hara, Kelly A McCorkell
Transplantation and Cellular Therapy. 2024-10-01
1 citations
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact...
Chetan Jeurkar, Benjamin Leiby, Shaik Rashid, Usama Gergis, Dolores Grossso
European Journal of Haematology. 2024-09-01
2 citations
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.
Dolores Grosso, John L Wagner, Allyson O'Connor, Kaitlyn Keck, Yanping Huang
Blood Advances. 2024-08-13

Grant Support

Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1999–2001
Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1997–1999